

FINDING OF NO SIGNIFICANT IMPACT

for

Monensin for Quail

Elanco Products Company

NADA 038-878 C086

NADA 130-736 C008

The Center for Veterinary Medicine has carefully considered the potential environmental impact of this action and has concluded that this action will not have a significant effect on the quality of the human environment and that an environmental impact statement therefore will not be prepared.

Elanco has submitted two identical supplemental NADA's for the purpose of requesting approval to add an indication to their previously approved monensin COBAN Medicated Type A Article (premix). The indication would be for prevention of coccidiosis in Bobwhite quail caused by Eimeria dispersa and E. lettyae. Monensin would be present in the complete feed of quail at 73 grams per ton.

In support of their applications, the firm has submitted an environmental assessment, dated January 1988, which addresses the potential environmental impacts due to the manufacture of the product and medicated feeds. Environmental assessment of the use of the product has already been completed in a Public Master File (5014). Together, these documents adequately show that the manufacture and use of monensin for quail will not be expected to cause significant environmental impacts.

5/11/88
Date

Thomas V. Raines 5/11/88
Primary Action Officer, HFV-135

5-10-88
Date

J. C. Matheson
Preparer and Chief,
Environmental Sciences Staff, HFV-162

Attachments (2)

Best Copy Available

cc: ~~Orig.~~ & Dup., (NADA 038-878 C086 A1; NADA 130-736 C008 A1)
Office File, HFV-162
Reading Board, HFV-162

JCMatheson:cbm:5/10/88(p/F#43)

Best Copy Available